Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company dedicated to tackling endocrine diseases and endocrine-related tumors. Their primary product candidate, Paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 agonist that has already completed its phase III clinical trial. The product is aimed at treating acromegaly and has also undergone a phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also in the process of developing CRN04777, another oral selective nonpeptide somatostatin type 5 receptor agonist, presently undergoing its phase I clinical trial. This product aims to help treat congenital hyperinsulinism. Additionally, CRN04894, an oral adrenocorticotrophic hormone antagonist, is currently undergoing its own phase I clinical trials. This product is aimed specifically for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was established in 2008 and has made its home in San Diego, California.
Crinetics Pharmaceuticals's ticker is CRNX
The company's shares trade on the NASDAQ stock exchange
They are based in San Diego, California
There are 51-200 employees working at Crinetics Pharmaceuticals
It is crinetics.com
Crinetics Pharmaceuticals is in the Healthcare sector
Crinetics Pharmaceuticals is in the Biotechnology industry
The following five companies are Crinetics Pharmaceuticals's industry peers: